Other Biopharmaceuticals

Daiichi Sankyo Company, Limited

Daiichi Sankyo Announces 2030 Fiscal Year Goals and Strategies

Daiichi Sankyo Healthcare to Raise Drug Prices Up to 40%

Daiichi Sankyo's Pexidartinib Fails to Gain Approval in China

Suntory Holdings Plans to Acquire Daiichi Sankyo Healthcare

ATLATL Innovation Center Reaches Biotech Innovation Cooperation Agreement with Daiichi Sankyo

Daiichi Sankyo Receives Approval for New Drug Enhertu

Daiichi Sankyo and BostonGene Partner to Accelerate Drug Development with AI

BostonGene Partners with Daiichi Sankyo to Integrate AI into Antibody Drug Development

 Daiichi Sankyo Submits Supplementary New Drug Application for DATROWAY®

Daiichi Sankyo's Trastuzumab Deruxtecan New Indication Receives Breakthrough Therapy Designation

 Daiichi Sankyo Initiates DS3790 Clinical Trial

Daiichi Sankyo Reports Strong Sales Growth for Enhertu

Daiichi Sankyo Co Ltd ADR Stock Volume Significantly Increased

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

AstraZeneca

Daiichi Sankyo

AstraZeneca PLC

FDA approves Enhertu for two HER2-positive early breast cancer indications

DSNKY

4568

The FDA has expanded the use of Enhertu (trastuzumab deruxtecan) for HER2-positive Stage II and III breast cancer, approving it for neoadjuvant and adjuvant settings. The neoadjuvant approval is based on the DESTINY-Breast11 trial, showing a 67.3% pathologic complete response. The adjuvant approval, based on DESTINY-Breast05, demonstrated a 53% reduction in recurrence risk. These approvals enhance treatment options and have significant financial implications, including $155 million in milestone payments.

Pharmexec

<![CDATA[FDA Expands Enhertu in Early HER2-Positive Breast Cancer]]>

Daiichi Sankyo Co. Ltd. reported a 12.1% decline in net income for the fiscal year ending March 31, 2026, with profit attributable to owners at 259.87 billion yen. Earnings per share fell to 140.37 yen. Despite a revenue increase to 2.12 trillion yen, operating profit dropped 31% to 229.09 billion yen. For FY27, the company projects revenue of 2.28 trillion yen and profit of 260 billion yen, with earnings per share expected at 142.88 yen. The stock rose 2.04% to JPY 2,649 on the Tokyo Stock Exchange.

rttnews

Daiichi Sankyo Earnings Fall; Guides FY27

Daiichi Sankyo has unveiled a new Five-Year Business Plan (FY2026 - FY2030) aimed at achieving over 2.3 trillion yen in oncology revenue by 2030 and becoming a top five global oncology company by 2035. The plan focuses on launching 20 new indications across five medicines, enhancing clinical development capabilities, and leveraging its DXd antibody drug conjugate platform. Financial targets include an operating profit exceeding 600 billion yen by 2030 and a progressive dividend policy. The company aims to accelerate innovation through advanced research and operational excellence, contributing to sustainable healthcare solutions.

MorningStar

Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation

Daiichi Sankyo and Waiv partner for ADC biomarkers

Shares of Daiichi Sankyo fell nearly 11% to 2,497.50 yen after the company delayed its earnings report for the fiscal year ending March 2026 to May 11, citing a review of its oncology portfolio and contract manufacturing provisions. The company also plans to release its five-year business plan for 2026-2030 on the same date. This delay occurs as Daiichi Sankyo shifts towards innovative drug discovery, having recently sold its over-the-counter drug business to Suntory Holdings for $1.55 billion. The stock is down nearly 26% this year.

Suntory Beverage & Food Ltd.

Suntory Beverage & Food Limited

Shares of Japanese Drugmaker Daiichi Sankyo Tumble on Delay in Earnings

Daiichi Sankyo announced a Phase 2 clinical study for ifinatamab deruxtecan (I-DXd) targeting advanced esophageal squamous cell cancer. The open-label trial evaluates tumor response in patients who have undergone prior treatments. The study aims to assess the drug's efficacy and safety, with updates indicating active recruitment. This development enhances Daiichi Sankyo's ADC pipeline, potentially increasing its market value and competitive position against firms like Merck and AstraZeneca. Investors should monitor interim data for insights into long-term revenue prospects and partnerships.

Tip Ranks

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

VG Health

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

VanEck Biotech ETF

Health Care Select Sector SPDR

iShares US Pharma

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares Biotechnology ETF

Merck

Daiichi Sankyo Advances ADC Pipeline With New Esophageal Cancer Study

South Korea's healthcare sector is booming, creating new billionaires as pharmaceutical companies pursue lucrative partnerships. Yoon Dae-in of Sam Chun Dang Pharm, with a net worth of $5.9 billion, ranks 10th among the nation's richest after a deal with Daiichi Sankyo for a weight-loss product. New entrants include Lee Sang-hoon of ABL Bio ($1.4 billion) and Hyuntae Kim of Voronoi ($1.3 billion). The rise of healthcare fortunes reflects a shift towards advanced R&D, with Korean firms signing more joint research agreements with global companies, marking a significant transition in the industry.

Daiichi Sankyo Company, Limited(4568.JP)